Search research articles
Contact Us
Filters
Showing results (411-420 of 981) with videos related to
Page
of 99
Sort By:
Frontiers in Endocrinology
|
January 30, 2020
Aging and Imaging Assessment of Body Composition: From Fat to Facts
Federico Ponti, Aurelia Santoro, Daniele Mercatelli, et al.
Neuron
|
October 8, 2013
Plasticity of recurrent l2/3 inhibition and gamma oscillations by whisker experience
Yu R Shao, Brian R Isett, Toshio Miyashita, et al.
Frontiers in Neurology
|
December 17, 2020
Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis
Antonio Giorgio, Marco Battaglini, Giordano Gentile, et al.
Therapeutic Advances in Neurological Disorders
|
May 23, 2022
Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
Raymond Hupperts, Claudio Gasperini, Jan Lycke, et al.
Eclinicalmedicine
|
January 31, 2024
Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial
Rossana Sanchez Russo, Serena Gasperini, Gillian Bubb, et al.
Neuroradiology
|
May 1, 1996
High-dose contrast-enhanced MRI in multiple sclerosis
T Koudriavtseva, C Pozzilli, C Di Biasi, et al.
Journal of the American Medical Directors Association
|
December 11, 2012
Prevalence and potentially reversible factors associated with anorexia among older nursing home residents: results from the ULISSE project
Francesco Landi, Fabrizia Lattanzio, Giuseppina Dell'Aquila, et al.
Glycobiology
|
December 22, 2018
Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation
Rossella Indellicato, Rossella Parini, Ruben Domenighini, et al.
BMC Neurology
|
October 15, 2009
Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study
Emilia Sbardella, Valentina Tomassini, Claudio Gasperini, et al.
Journal of Neurology
|
September 10, 2005
Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis
Valentina Tomassini, Andrea Paolillo, Pierluigi Russo, et al.
Page
of 99
Search research articles
Search
Showing results (411-420 of 981) with videos related to
Sort By:
Page
of 99
Frontiers in Endocrinology
|
January 30, 2020
Aging and Imaging Assessment of Body Composition: From Fat to Facts
Federico Ponti, Aurelia Santoro, Daniele Mercatelli, et al.
Neuron
|
October 8, 2013
Plasticity of recurrent l2/3 inhibition and gamma oscillations by whisker experience
Yu R Shao, Brian R Isett, Toshio Miyashita, et al.
Frontiers in Neurology
|
December 17, 2020
Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis
Antonio Giorgio, Marco Battaglini, Giordano Gentile, et al.
Therapeutic Advances in Neurological Disorders
|
May 23, 2022
Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
Raymond Hupperts, Claudio Gasperini, Jan Lycke, et al.
Eclinicalmedicine
|
January 31, 2024
Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial
Rossana Sanchez Russo, Serena Gasperini, Gillian Bubb, et al.
Neuroradiology
|
May 1, 1996
High-dose contrast-enhanced MRI in multiple sclerosis
T Koudriavtseva, C Pozzilli, C Di Biasi, et al.
Journal of the American Medical Directors Association
|
December 11, 2012
Prevalence and potentially reversible factors associated with anorexia among older nursing home residents: results from the ULISSE project
Francesco Landi, Fabrizia Lattanzio, Giuseppina Dell'Aquila, et al.
Glycobiology
|
December 22, 2018
Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation
Rossella Indellicato, Rossella Parini, Ruben Domenighini, et al.
BMC Neurology
|
October 15, 2009
Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study
Emilia Sbardella, Valentina Tomassini, Claudio Gasperini, et al.
Journal of Neurology
|
September 10, 2005
Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis
Valentina Tomassini, Andrea Paolillo, Pierluigi Russo, et al.
Page
of 99